These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-003739-30 Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM] not-yet-due
Ongoing 2004-004320-13 RANDOMIZED PHASE III-STUDY ON VALPROIC ACID IN COMBINATION WITH ALL-TRANS RETINOIC ACID, STANDARD INDUCTION- AND CONSOLIDATION THERAPY IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA not-yet-due
Ongoing 2004-004321-95 RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATIENT... not-yet-due
Ongoing 2004-004509-11 Efficiency and tolerability of L-Dopa in patients with Hereditary Spastic Paraplegia (HSP) not-yet-due
Not reported 2005-000771-18 Prospective, doubleblind, randomized multicenter study to proof the clinical and bacteriological non-inferiority of amoxicillin versus moxifloxacin in hospitalized patients with non-severe community-... 2011-01-31 due-trials
Not reported 2005-004236-40 Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer 2013-04-18 due-trials
Not reported 2006-000171-15 Randomized, placebo-controlled, double-blinded study evaluating the effects of Pioglitazone on intima-media-thickness (IMT) of the carotid arteries measured by MRI in non-diabetic patients with confir... 2010-09-10 due-trials
Not reported Terminated 2006-005410-13 EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE). 2010-04-28 due-trials
Not reported Terminated 2007-000443-99 Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study for p... 2008-10-31 due-trials
Not reported 2007-001565-15 Konzentrationen von Ertapenem in kolorektalem Gewebe. 2009-12-31 due-trials
Ongoing 2007-003099-20 A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphoc... not-yet-due
Not reported 2008-005453-38 Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies SUCCESS C-Trial 2017-03-31 due-trials
Exempt, with results 2008-008238-35 Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed ... 2015-11-30 not-yet-due
Not reported 2009-010738-23 Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage 2016-09-14 due-trials
Ongoing 2009-011889-28 Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation not-yet-due
Not reported Terminated 2009-013956-62 Preparation of Neuroplant® 300mg N in film-coated tablets (St. John´s wort, SJW) in the treatment of mild to moderate Major Depressive Disorder (MDD) in adolescents from 12 to 17 years (inclusive): a ... 2012-08-29 due-trials
Reported results 2009-016142-44 Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine 2016-10-02 due-trials
Listed as ongoing, but also has a completion date 2009-016994-13 EUropean Pharmacogenetics of AntiCoagulation Therapy trial 2013-03-25 bad-data
Exempt 2010-023022-20 A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents ... 2013-11-06 not-yet-due
Completed, report not yet due 2010-023409-37 Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 M... 2018-07-13 not-yet-due
Ongoing 2010-024094-39 Offene, monozentrische, nicht kontrollierte und nicht randomisierte Phase IV-Studie zur Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten. not-yet-due
Ongoing 2010-024238-46 DETECT III – A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus Lapatinib in patients with initially HER2-negative metastatic breast cancer and H... not-yet-due
Ongoing 2011-003168-63 Phase-II study evaluating midostaurin in induction, consolidation and not-yet-due
Not reported 2011-004482-32 Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) 2016-04-28 due-trials
Not reported Terminated 2012-001134-33 Randomized, Double-Blind, Placebo-Controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients with Congestive Heart Failure 2014-12-31 due-trials
Exempt 2012-002431-29 A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis 2013-03-22 not-yet-due
Ongoing 2012-005657-24 Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, m... not-yet-due
Ongoing 2013-000506-37 Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia not-yet-due
Completed, but no date Terminated 2013-001550-98 Prospective controlled phase 2 trial of cabazitaxel in patients with temozolomide refractory glioblastoma multiforme (GBM) bad-data
Ongoing 2013-003117-18 Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) not-yet-due
Ongoing 2014-000174-19 Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A not-yet-due
Exempt Terminated 2014-000477-39 Dose Finding safety run in Phase followed by a randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly ... 2016-11-28 not-yet-due
Completed, but no date Terminated 2014-002236-14 Phenprocoumon versus Dabigatran in subjects with atrial fibrillation and left atrial thrombus - a prospective, randomized, controlled, open-label one year follow-up pilot study bad-data
Ongoing 2014-002249-22 DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzu... not-yet-due
Exempt 2014-003647-34 Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemias not-yet-due
Exempt 2014-004197-42 A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for rec... not-yet-due
Ongoing 2015-004606-41 A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II TRIAL OF IBRUTINIB PLUS VENETOCLAX PLUS OBINUTUZUMAB IN PHYSICALLY FIT (CIRS ≤ 6 & NORMAL CREATININE CLEARANCE) OR UNFIT (CIRS >6 OR CREATININE CLEARANC... not-yet-due
Ongoing 2016-002550-20 Allogeneic microbiota-reconstitution (AMR) for the Treatment of patients with diarrhea-predominant irritable bowel Syndrome (IBS-D) - the AMIRA trial not-yet-due
Ongoing 2017-003149-56 OBINUTUZUMAB in MARGINAL ZONE LYMPHOMA not-yet-due
Ongoing 2017-004362-95 Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia not-yet-due